Cargando…

How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?

BACKGROUND: There is increasing interest in patient-reported measures of cancer treatment tolerability. A global measure of bother, the FACT GP5 item (“I am bothered by side effects of treatment”) is potentially useful for regulatory, research, and clinical use. To understand this item’s appropriate...

Descripción completa

Detalles Bibliográficos
Autores principales: Peipert, John Devin, Shaunfield, Sara, Kaiser, Karen, Moreno, Patricia I., Fox, Rina S., Kircher, Sheetal, Mohindra, Nisha, Ip, Edward, Zhao, Fengmin, Wagner, Lynne, Cella, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356672/
https://www.ncbi.nlm.nih.gov/pubmed/36525100
http://dx.doi.org/10.1007/s00520-022-07484-7
_version_ 1785075329599012864
author Peipert, John Devin
Shaunfield, Sara
Kaiser, Karen
Moreno, Patricia I.
Fox, Rina S.
Kircher, Sheetal
Mohindra, Nisha
Ip, Edward
Zhao, Fengmin
Wagner, Lynne
Cella, David
author_facet Peipert, John Devin
Shaunfield, Sara
Kaiser, Karen
Moreno, Patricia I.
Fox, Rina S.
Kircher, Sheetal
Mohindra, Nisha
Ip, Edward
Zhao, Fengmin
Wagner, Lynne
Cella, David
author_sort Peipert, John Devin
collection PubMed
description BACKGROUND: There is increasing interest in patient-reported measures of cancer treatment tolerability. A global measure of bother, the FACT GP5 item (“I am bothered by side effects of treatment”) is potentially useful for regulatory, research, and clinical use. To understand this item’s appropriateness for capturing treatment tolerability, we conducted cognitive interviews on this item with 3 samples of cancer patients. METHODS: Patients with ovarian cancer (Study 1: N = 21; on treatment), lymphoma (Study 2: N = 14; on treatment), and colorectal or lung cancer (Study 3: N = 16; treatment naïve) were interviewed about GP5’s understandability and relevance to their treatment side effects. What patients think about when answering GP5 was also assessed. In all studies, the interview included both structured and open-ended questions. Qualitative data were coded to extract themes and responses to structured questions were tallied. RESULTS: Most patients on treatment (Studies 1 and 2) reported that the GP5 item wording is appropriate (88%) and its meaning is clear (97%). They were very confident or confident in their response (97%) and stated that GP5 was relevant to their cancer experience (97%). When answering GP5, patients considered their treatment and specific side effects. A large proportion (40%) of the treatment-naïve (Study 3) patients reported that GP5 was not relevant to their cancer treatment, and the largest proportion responded to GP5 thinking of negative side effect expectancies. CONCLUSION: This study provides assurance that GP5 is a useful indicator of treatment tolerability, and is meaningful to people with cancer, especially once they have started treatment.
format Online
Article
Text
id pubmed-10356672
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-103566722023-07-21 How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability? Peipert, John Devin Shaunfield, Sara Kaiser, Karen Moreno, Patricia I. Fox, Rina S. Kircher, Sheetal Mohindra, Nisha Ip, Edward Zhao, Fengmin Wagner, Lynne Cella, David Support Care Cancer Research BACKGROUND: There is increasing interest in patient-reported measures of cancer treatment tolerability. A global measure of bother, the FACT GP5 item (“I am bothered by side effects of treatment”) is potentially useful for regulatory, research, and clinical use. To understand this item’s appropriateness for capturing treatment tolerability, we conducted cognitive interviews on this item with 3 samples of cancer patients. METHODS: Patients with ovarian cancer (Study 1: N = 21; on treatment), lymphoma (Study 2: N = 14; on treatment), and colorectal or lung cancer (Study 3: N = 16; treatment naïve) were interviewed about GP5’s understandability and relevance to their treatment side effects. What patients think about when answering GP5 was also assessed. In all studies, the interview included both structured and open-ended questions. Qualitative data were coded to extract themes and responses to structured questions were tallied. RESULTS: Most patients on treatment (Studies 1 and 2) reported that the GP5 item wording is appropriate (88%) and its meaning is clear (97%). They were very confident or confident in their response (97%) and stated that GP5 was relevant to their cancer experience (97%). When answering GP5, patients considered their treatment and specific side effects. A large proportion (40%) of the treatment-naïve (Study 3) patients reported that GP5 was not relevant to their cancer treatment, and the largest proportion responded to GP5 thinking of negative side effect expectancies. CONCLUSION: This study provides assurance that GP5 is a useful indicator of treatment tolerability, and is meaningful to people with cancer, especially once they have started treatment. Springer Berlin Heidelberg 2022-12-16 2023 /pmc/articles/PMC10356672/ /pubmed/36525100 http://dx.doi.org/10.1007/s00520-022-07484-7 Text en © ©The Author(s) 2022, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Peipert, John Devin
Shaunfield, Sara
Kaiser, Karen
Moreno, Patricia I.
Fox, Rina S.
Kircher, Sheetal
Mohindra, Nisha
Ip, Edward
Zhao, Fengmin
Wagner, Lynne
Cella, David
How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?
title How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?
title_full How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?
title_fullStr How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?
title_full_unstemmed How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?
title_short How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?
title_sort how do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356672/
https://www.ncbi.nlm.nih.gov/pubmed/36525100
http://dx.doi.org/10.1007/s00520-022-07484-7
work_keys_str_mv AT peipertjohndevin howdopatientsinterpretandrespondtoasingleitemglobalindicatorofcancertreatmenttolerability
AT shaunfieldsara howdopatientsinterpretandrespondtoasingleitemglobalindicatorofcancertreatmenttolerability
AT kaiserkaren howdopatientsinterpretandrespondtoasingleitemglobalindicatorofcancertreatmenttolerability
AT morenopatriciai howdopatientsinterpretandrespondtoasingleitemglobalindicatorofcancertreatmenttolerability
AT foxrinas howdopatientsinterpretandrespondtoasingleitemglobalindicatorofcancertreatmenttolerability
AT kirchersheetal howdopatientsinterpretandrespondtoasingleitemglobalindicatorofcancertreatmenttolerability
AT mohindranisha howdopatientsinterpretandrespondtoasingleitemglobalindicatorofcancertreatmenttolerability
AT ipedward howdopatientsinterpretandrespondtoasingleitemglobalindicatorofcancertreatmenttolerability
AT zhaofengmin howdopatientsinterpretandrespondtoasingleitemglobalindicatorofcancertreatmenttolerability
AT wagnerlynne howdopatientsinterpretandrespondtoasingleitemglobalindicatorofcancertreatmenttolerability
AT celladavid howdopatientsinterpretandrespondtoasingleitemglobalindicatorofcancertreatmenttolerability